Protocol Ledger

NCT05345171 · Phase III · ACTIVE NOT RECRUITING

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Interventional Phase III clinical trial protocol NCT05345171 sponsored by Ultragenyx Pharmaceutical in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-18 Enrollment: 37 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05345171
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)37 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05345171
Protocol FieldVerified Registry Value
NCT IdentifierNCT05345171
Consolidated Lead SponsorUltragenyx Pharmaceutical
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment37 participants (ACTUAL)
Registered Start Date2022-10-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Ultragenyx Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI